Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change

This article was originally published in The Pink Sheet Daily

Executive Summary

FAERS reports identify cases of diabetic ketoacidosis, ordinarily rare in type 2 diabetes, which were not associated with high blood sugar levels.

You may also be interested in...



Product Liability Litigation Playbook: Pros And Cons For Pharma

Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.

Invokana, Farxiga New Safety Warning May Give Jardiance Market Edge

FDA strengthens warning about risk of acute kidney injury for two SGLT2 inhibitors but not Jardiance, the only diabetes drug with data on cardiovascular benefit.

SGLT2 Inhibitors' Warning On Ketoacidosis Recommends Drug Holidays

Sponsors must also conduct another post-marketing study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel